Evidence to Policy Initiative, Global Health Group, University of California San Francisco, 50 Beale Street, San Francisco, CA, 94105, USA.
Bull World Health Organ. 2012 Jun 1;90(6):452-60. doi: 10.2471/BLT.11.091199. Epub 2012 Feb 3.
The Affordable Medicines Facility-malaria is an innovative financing mechanism, managed by the Global Fund to Fight AIDS, Tuberculosis and Malaria. This initiative aims to increase the use of artemisinin-based combination therapies for treating malaria. A pilot is underway in eight countries to determine whether the mechanism reduces the consumer price of these drugs and increases their availability in public and private outlets, their market share and their use. To evaluate the pilot, an analysis was done to estimate predetermined "benchmarks" of success at 1 and 2 years. The analysis used a mixed-methods approach, triangulating data from a literature review with information from 33 interviews with experts. A sensitivity analysis and other methods were used to verify the results. Benchmarks used to determine success include an increase in availability of artemisinin-based combination therapies of 40 percentage points from baseline, and an increase in their use of 10-15 percentage points from baseline at year 2. These benchmarks were based on evidence that national public health programmes aimed at increasing the use of a specific health commodity in developing countries have generally achieved only modest changes in use within a 2-year time frame. Evaluation should also take individual country contexts into account.
抗疟药品采购促进基金是一个创新融资机制，由全球抗击艾滋病、结核病和疟疾基金负责管理。该倡议旨在促进采用以青蒿素为基础的联合疗法治疗疟疾。目前正在八个国家开展试点，以确定该机制是否能降低这些药品的消费者价格，增加公共和私人渠道的供应、提高其市场份额并增加其使用量。为了评估试点情况，开展了一项分析，以估计在第 1 年和第 2 年达到预先设定的“成功基准”的情况。分析采用了混合方法，将文献综述中的数据与对 33 名专家的访谈信息进行了三角验证。还采用了敏感性分析和其他方法来验证结果。成功基准包括与基线相比，青蒿素为基础的联合疗法的供应增加 40 个百分点，以及与基线相比，第二年的使用量增加 10-15 个百分点。这些基准是基于这样的证据，即发展中国家旨在提高某种特定卫生商品使用率的国家公共卫生方案，在两年时间内，通常只能实现使用量的适度变化。评估还应考虑到个别国家的情况。
